AU6477890A - Glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof incombination with functionalized tumor-specific enzyme conjugates - Google Patents

Glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof incombination with functionalized tumor-specific enzyme conjugates

Info

Publication number
AU6477890A
AU6477890A AU64778/90A AU6477890A AU6477890A AU 6477890 A AU6477890 A AU 6477890A AU 64778/90 A AU64778/90 A AU 64778/90A AU 6477890 A AU6477890 A AU 6477890A AU 6477890 A AU6477890 A AU 6477890A
Authority
AU
Australia
Prior art keywords
glycosyl
specific enzyme
preparation
enzyme conjugates
incombination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU64778/90A
Other versions
AU638064B2 (en
Inventor
Klaus Bosslet
Jorg Czech
Cenek Kolar
Hans-Harald Sedlacek
Gerhard Seemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of AU6477890A publication Critical patent/AU6477890A/en
Application granted granted Critical
Publication of AU638064B2 publication Critical patent/AU638064B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to glycosyl-etoposide prodrugs, process for their preparation and their use in combination with functionalised tumour-specific enzyme conjugates for the treatment of cancers, and it specifically relates to 4'-O-glycosyl-etoposides as prodrugs which can be cleaved to cytotoxic agents on exposure to tumour-specific enzyme conjugates, where the liberated agent is suitable, by reason of its cytostatic activity, for the treatment of cancers.
AU64778/90A 1989-10-20 1990-10-19 Glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof incombination with functionalized tumor-specific enzyme conjugates Ceased AU638064B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3935016A DE3935016A1 (en) 1989-10-20 1989-10-20 GLYCOSYL ETOPOSIDE PRODRUGS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN COMBINATION WITH FUNCTIONALIZED TUMOR-SPECIFIC ENZYME CONJUGATES
DE3935016 1989-10-20

Publications (2)

Publication Number Publication Date
AU6477890A true AU6477890A (en) 1991-04-26
AU638064B2 AU638064B2 (en) 1993-06-17

Family

ID=6391872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64778/90A Ceased AU638064B2 (en) 1989-10-20 1990-10-19 Glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof incombination with functionalized tumor-specific enzyme conjugates

Country Status (12)

Country Link
EP (1) EP0423747B1 (en)
JP (1) JP3293086B2 (en)
KR (1) KR910007948A (en)
AT (1) ATE168695T1 (en)
AU (1) AU638064B2 (en)
CA (1) CA2028086A1 (en)
DE (2) DE3935016A1 (en)
DK (1) DK0423747T3 (en)
ES (1) ES2119738T3 (en)
GR (1) GR3027569T3 (en)
IE (1) IE903764A1 (en)
PT (1) PT95620B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US7241595B2 (en) * 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE68928946T2 (en) * 1989-12-11 1999-10-21 Immunomedics Inc METHOD FOR DETECTING DIAGNOSTIC OR THERAPEUTIC AGENTS BY ANTIBODIES
FR2676058B1 (en) * 1991-04-30 1994-02-25 Hoechst Lab GLYCOSYLATED PRODUCTS, THEIR PREPARATION PROCESS AND THEIR USE IN THE TREATMENT OF CANCERS.
IT1250692B (en) * 1991-07-23 1995-04-21 PROCEDURE FOR THE PREPARATION OF DEMETYLEPIPODOPHYLOTOXY-BETA-D-GLUCOSIDES.
DE4236237A1 (en) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, their preparation and use as medicines
DE19702988A1 (en) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazole and crotonic acid amide derivatives and their use as pharmaceuticals and diagnostics
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
WO2001049693A1 (en) * 2000-01-03 2001-07-12 Korea Research Institute Of Chemical Technology 4-O-[2-(N,N-DIALKYLAMINO)-2-DEOXY-4,6-O,O-beta-D-GLUCOSYL]-4'-O-DEMETHYL-EPI-PODOPHYLLOTOXIN, DERIVATIVES, AND AN ANTICANCER COMPOSITION CONTAINING SAME
WO2003035661A1 (en) * 2001-10-26 2003-05-01 Centre National De La Recherche Scientifique Derivatives of etoposide and analogs, and pharmaceutical compositions containing them
ATE483714T1 (en) 2001-12-03 2010-10-15 Universitaetsklinikum Charite PODOPHYLLOTOXINS AS ANTIPROLIFERATIVE AGENTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3329184A1 (en) * 1983-08-12 1985-02-21 Behringwerke Ag, 3550 Marburg MONOCLONAL ANTIBODIES WITH SPECIFICITY FOR MEMBRANE-ASSOCIATED ANTIGENS
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
DE4002888A1 (en) * 1990-02-01 1991-08-08 Behringwerke Ag ANTHRACYCLIN-GLYCOSYL PRODRUGS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN COMBINATION WITH FUNCTIONALIZED TUMOR-SPECIFIC ENZYME CONJUGATES

Also Published As

Publication number Publication date
ES2119738T3 (en) 1998-10-16
IE903764A1 (en) 1991-04-24
PT95620A (en) 1991-09-13
PT95620B (en) 1997-08-29
DE59010838D1 (en) 1998-08-27
JP3293086B2 (en) 2002-06-17
AU638064B2 (en) 1993-06-17
JPH03135993A (en) 1991-06-10
ATE168695T1 (en) 1998-08-15
EP0423747B1 (en) 1998-07-22
GR3027569T3 (en) 1998-11-30
KR910007948A (en) 1991-05-30
DE3935016A1 (en) 1991-04-25
EP0423747A3 (en) 1991-09-11
DK0423747T3 (en) 1999-04-26
EP0423747A2 (en) 1991-04-24
CA2028086A1 (en) 1991-04-21

Similar Documents

Publication Publication Date Title
AU8458891A (en) A process for the preparation of carnosic acid and the use of the acid for its anticarcinogenic and antiviral properties
WO1997002046A3 (en) Saccharide conjugates
IL107874A (en) Compositions comprising nanoparticles containing a diagnostic or therapeutic agent and tyloxapol adsorbed thereon and their preparation
AU6477890A (en) Glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof incombination with functionalized tumor-specific enzyme conjugates
EP0426368A3 (en) Compositions containing derivatives of chitin for preventing adhesion
AU628095B2 (en) Chelants possessing ortho ligating functionality and complexes thereof
GR3015634T3 (en) Process for the preparation of micronised biodegradable particles.
AU633867B2 (en) Delivery of cytotoxic agents
WO1989012380A3 (en) Therapeutic uses of 2',5'-oligoadenylate derivatives
AU625802B2 (en) Immunotoxins for the treatment or prophylaxis of auto-immune diseases
AU7719491A (en) Therapeutic compound
EP0427402A3 (en) Treatment of shock by cyclodextrins and their derivatives
IT1242026B (en) Pharmaceutical composition containing a ferro-schizokinen complex for the treatment of iron deficiency anaemia.

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired